IceCure Medical has highlighted a study showing the potential of the company's ProSense cryoablation system. The research was presented at the recent European Society of Breast Imaging (EUSOBI) annual meeting in Valencia, Spain.
ProSense is a minimally invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, which may be useful in women deemed inoperable for breast cancer.
During the study, ultrasound-guided cryoablation using ProSense was performed on 28 women with a median age of 73.4. The women had biopsy-proven malignant lesions and were deemed inoperable. Of the total, 14 women were diagnosed with molecular subtype luminal-A tumors and the other 14 were diagnosed with luminal-B tumors. The women were monitored at one, three, and six months postprocedure, and tumor size reduction rate was evaluated by ultrasound.
The study authors reported the following size reduction rates:
- One month: 21.59% for luminal-A vs. 19.83% for luminal-B
- Three months: 70.16% for luminal-A vs. 60.71% for luminal-B
- Six months: 96.81% for luminal-A vs. 93.43% for luminal-B
The study also found that for the luminal-A group, there was an absence of residual malignant cells in all biopsy samples and a disappearance of lesions.
IceCure said the results validate similar results seen in the longer-term five-year post-procedure ICE3 study. The Israeli company said it expects the study to conclude in the first quarter of 2024.
